This is a type of cancer that starts in the lining of the uterus (endometrium). It's a common type of ovarian cancer.
Every report comes from a Lived member, sent anonymously.
Have you had Hysterectomy for Endometrioid Carcinoma?
Endometrioid carcinoma is a cancer whose cells look like the glandular cells that normally line the uterus (the endometrium). The name describes how the tumor looks under a microscope. It is by far the most common form of endometrial cancer, the cancer that starts in the lining of the uterus, making up about three in four cases. It can also start in an ovary, where it accounts for roughly one in ten of the ovarian cancers that arise from the ovary's surface tissue. Occasionally it is found in the uterus and an ovary at the same time. In the uterus, the usual first sign is abnormal vaginal bleeding, especially any bleeding after menopause. Because that bleeding tends to appear early, most endometrioid cancers of the uterus are found while still confined to the uterus, when surgery alone is often enough. In the ovary, early disease causes fewer clues, such as pelvic pressure, bloating or feeling full quickly, so it can be harder to notice. Pathologists also grade these tumors. Low-grade (grade 1 or 2) tumors still look fairly organized and tend to grow slowly. High-grade (grade 3) tumors look more disorganized and behave less predictably. Grade, stage and newer molecular tests together shape both the outlook and the treatment plan.
In the uterus, this cancer is closely tied to estrogen. Estrogen makes the uterine lining grow, and progesterone normally balances it. When the lining is exposed to estrogen for a long time without enough progesterone, it can thicken (endometrial hyperplasia), and some thickened linings with abnormal cells go on to become cancer. That explains many of the known risk factors: obesity, which raises estrogen levels; irregular or absent ovulation, as in polycystic ovary syndrome (PCOS); an early first period or late menopause; never having been pregnant; and taking estrogen-only hormone therapy after menopause while still having a uterus. Combined estrogen-plus-progestin therapy does not carry that added risk. Tamoxifen, a breast cancer medicine that acts like estrogen on the uterus, also raises risk. Older age, type 2 diabetes and metabolic syndrome add to it. Inherited risk matters too. Lynch syndrome, an inherited condition affecting the genes that repair copying errors in DNA (mismatch repair genes), raises the risk of endometrial, ovarian and colorectal cancers. Having a mother, sister or daughter with endometrial cancer also increases risk. In the ovary, endometrioid carcinoma is linked to endometriosis, a condition in which tissue similar to the uterine lining grows outside the uterus. These are risk factors, not proven causes in any one person. Many people with several of them never develop this cancer, and some people develop it without any.
For possible uterine cancer, evaluation usually starts with a pelvic exam and a transvaginal ultrasound, in which a small probe placed in the vagina shows the thickness of the uterine lining. Confirming the diagnosis requires a sample of the lining itself. This is often an office endometrial biopsy, where a thin tube draws out a small piece of tissue, or a dilation and curettage (D&C) or hysteroscopy, in which a thin camera looks inside the uterus. A Pap test checks the cervix and is not a reliable way to find this cancer. For an ovarian mass, imaging such as ultrasound, CT scans or MRI scans, along with a blood test for CA-125, helps judge how suspicious it looks. CA-125 is a protein that ovarian cancer can raise, but benign conditions such as endometriosis can raise it too, so it cannot settle the question alone. Often the diagnosis is confirmed only when the mass is removed in surgery and examined. Once cancer is confirmed, the pathologist reports its type and grade, and surgery establishes the stage: whether the cancer has grown deep into the uterine wall or beyond it, reached lymph nodes or spread farther. Stage I means it is still confined to where it started. Tumor tissue is now commonly tested to sort it into one of four molecular groups: POLE-mutated (a change in POLE, a gene the cell uses to copy DNA), which generally has an excellent outlook; mismatch repair deficient (dMMR); p53-abnormal, a more aggressive group; and no specific molecular profile. These results refine the risk estimate and help decide who needs more treatment or might benefit from immunotherapy. A mismatch repair deficient result can also point to Lynch syndrome, which leads to genetic counseling and a blood test for an inherited cause that could matter for relatives.
Surgery is the main treatment for endometrioid cancer of the uterus. The standard operation removes the uterus and cervix (total hysterectomy) along with both ovaries and fallopian tubes, and usually checks nearby lymph nodes. Many centers use sentinel lymph node mapping, which removes only the first few nodes the tumor drains to rather than a full set. The operation can be done through an abdominal incision or with minimally invasive laparoscopic surgery; in a large trial, survival was the same either way. For most low-grade tumors confined to the uterus, surgery alone is all that is needed. When surgery shows features that make a return more likely, extra (adjuvant) treatment may follow. Radiation, either internal radiation placed in the top of the vagina (vaginal brachytherapy) or external radiation aimed at the pelvis, lowers the chance of the cancer coming back in that area. In trials for early-stage disease, it did not lengthen survival and it added side effects, which is why it is offered selectively rather than to everyone. Chemotherapy, typically carboplatin with paclitaxel, is used for higher-risk or more advanced disease. Molecular results increasingly steer these choices; POLE-mutated tumors, for example, often need no added treatment. For cancer that is advanced at diagnosis or has come back, immunotherapy has changed care. Pembrolizumab (Keytruda) and dostarlimab (Jemperli) are immune checkpoint inhibitors, antibodies that release a brake on the immune system so it can attack the cancer. Each is approved alongside carboplatin and paclitaxel for these situations, and the benefit is largest in mismatch repair deficient tumors. Hormone therapy with progestins is another option for tumors that carry hormone receptors. For a younger person who wants to keep the ability to become pregnant and has a grade 1 tumor confined to the uterine lining, carefully selected cases may be treated first with a progestin, taken as pills or delivered by a hormone-releasing intrauterine device (IUD), with repeated biopsies to check the response. This is not standard care for everyone: the cancer can persist or come back, so close follow-up and a plan for surgery are part of the approach. Endometrioid carcinoma of the ovary is treated as an ovarian cancer: surgery to remove the tumor and stage it, usually followed by platinum-based chemotherapy unless the cancer is low grade and confined to one ovary.
Outlook depends mainly on stage and, increasingly, on molecular group. Endometrioid cancer of the uterus is usually caught early. In the United States, about two thirds of uterine cancers are diagnosed while still confined to the uterus, and about 95% of people in that group are alive five years later. The figure is about 70% when the cancer has reached nearby lymph nodes or tissues, and about 20% when it has spread to distant organs. These numbers cover all uterine cancers, reflect people diagnosed years ago and cannot predict any one person's course. Removing the uterus ends periods and the possibility of pregnancy. If both ovaries are removed before natural menopause, menopause symptoms such as hot flashes usually begin right away, which is worth discussing before surgery. Radiation and chemotherapy bring their own side effects, which the care team can help manage. Follow-up visits continue after treatment ends, with exams and sometimes repeat tests, to check whether the cancer has come back. Anyone found to have Lynch syndrome may also need a plan for the other cancers it raises the risk of, and close relatives may choose genetic testing.
See a clinician about any vaginal bleeding after menopause, or bleeding that is unusually heavy, irregular or between periods, especially if you have risk factors such as obesity or Lynch syndrome. If you take tamoxifen, report any abnormal bleeding, since it calls for evaluation of the uterine lining. Bloating, pelvic pressure or pain, or feeling full quickly that does not go away also deserves an evaluation. If you have been treated, contact your care team promptly about new vaginal bleeding, pelvic pain or other new, persistent symptoms between scheduled follow-up visits, rather than waiting for the next appointment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Endometrioid Carcinoma is like, what's helped you, or ask the community a question.